Oncomedicine 2016; 1:25-27. doi:10.7150/oncm.16256 This volume
Short Research Paper
ERCC1 Biomarker in Colorectal Cancer: To Induce or Not to Induce? This Is the Matter!
1. Medical Oncology Department, Università Cattolica del Sacro Cuore, Rome, Italy;
2. Department of Biochemistry, Università Cattolica del Sacro Cuore, Rome, Italy;
3. Department of Medical Oncology, Fondazione Poliambulanza, Brescia, Italy.
Di Salvatore M, Orlandi A, Paolillo C, Aroldi F, Rodriquenz M, Capolongo E, Barone C. ERCC1 Biomarker in Colorectal Cancer: To Induce or Not to Induce? This Is the Matter!. Oncomedicine 2016; 1:25-27. doi:10.7150/oncm.16256. Available from /v01p0025.htm
In this short research communication, using circulating tumor cells (CTCs) as a “dynamic” tissue, we found that ERCC1 induction is significantly correlated with clinical outcome in colorectal cancer patients treated with oxaliplain-based therapy. This is the first report proposing the ability to induce ERCC1 as a blood-based biomarker for oxaliplatin resistance in metastatic colorectal cancer.
Keywords: CTC, ERCC1, oxaliplatin, colorectal cancer